U10 Full Member Application Affiliated with SWOG

SWOG 附属 U10 正式会员申请

基本信息

  • 批准号:
    8214704
  • 负责人:
  • 金额:
    $ 34.12万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2004
  • 资助国家:
    美国
  • 起止时间:
    2004-07-26 至 2015-12-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The University of Texas, MD Anderson Cancer Center (MDACC) is one of 3 NCI-designated cancer centers in Texas (and the only one designated as a Comprehensive Cancer Center). MDACC provides comprehensive services to cancer patients through 13 interdisciplinary care centers, integrating medical oncology, surgery, radiation oncology, nursing, pharmacology, and other care providers by disease site/type. During the previous granting period, U10 leadership has been seamlessly transitioned to an internationally recognized clinical investigator and thoracic/head and neck oncologist, Dr. Roy Herbst, with the continued involvement of the former U10 Chair, Dr. Scott Lippman, in the MDACC SWOG Executive committee. As documented in this proposal, MDACC has demonstrated increasing scientific contributions in the previous grant period, with 20 MDACC investigators listed as either primary author or co-author on 42 separate manuscripts and 30 abstracts either published or submitted for publication during this grant period. In addition, 20 investigators have served as either coordinator/co-coordinator of 23 trials in the last grant period, with 6 protocol/protocol concepts currently under development. MDACC has also exhibited year-over-year accrual increases, with 90 patients accrued in 2008, leading to an average accrual in the top third of all SWOG sites. Contributions to SWOG leadership have remained robust over the reporting period; 8 investigators currently hold leadership roles in SWOG, with an additional 5 investigators having held leadership positions in the previous grant period, thus allowing us to provide our multidisciplinary expertise and resources to SWOG, through the involvement of radiation oncologists, surgeons, and pathologists in SWOG leadership positions. MDACC, with significant input from MDACC SWOG staff, also created a Cooperative Group Support Services initiative to ensure awareness of and compliance with cooperative group reporting requirements at an institutional level. Finally, additional contributions include leadership roles in SELECT, PCPT, HIGPN, and other committees; five presentation given by MDACC faculty at Group meetings; and forthcoming intergroup collaborations with RTOG, among others. Future plans for the MDACC SWOG program include the expansion of our SWOG mentoring program for junior faculty. MDACC will continue to apply its strengths in developing multidisciplinary, innovative Phase II and III studies within the SWOG setting. We look fonward to leading SWOG efforts in cancer research, treatment, and prevention; thereby fulfilling our mission of eliminating cancer in Texas, the nation, and the world.
描述(由申请人提供): 德克萨斯大学医学部安德森癌症中心(MDACC)是德克萨斯州3个NCI指定的癌症中心之一(也是唯一一个指定为综合癌症中心)。MDACC通过13个跨学科护理中心为癌症患者提供综合服务,根据疾病部位/类型整合肿瘤内科、外科、放射肿瘤科、护理、药理学和其他护理提供者。在上一个授予期间,U10的领导层已经无缝过渡到国际公认的临床研究者和胸/头颈肿瘤学家Roy Herbst博士,前U10主席Scott Lippman博士继续参与MDACC SWOG执行委员会。如本提案所述,MDACC在上一个资助期内表现出越来越多的科学贡献,20名MDACC研究人员被列为42份单独手稿的主要作者或共同作者,30份摘要在本资助期内出版或提交出版。此外,在上一个赠款期间,20名调查员担任了23项试验的协调员/共同协调员,目前正在制定6项方案/方案概念。MDACC也显示出逐年增加的应计费用,2008年有90名患者应计费用,导致所有SWOG研究中心的平均应计费用达到前三分之一。在本报告所述期间,对SWOG领导层的贡献仍然强劲; 8名研究者目前在SWOG担任领导职务,另有5名研究者在上一个资助期担任领导职务,从而使我们能够通过放射肿瘤学家,外科医生和病理学家参与SWOG领导职务,为SWOG提供多学科的专业知识和资源。该中心在其工作人员的大力投入下,还制定了合作社支助服务倡议,以确保在机构一级了解和遵守合作社报告要求。最后,其他贡献包括在选择,PCPT,HIGPN和其他委员会的领导角色; MDACC教师在小组会议上的五次演讲;以及即将与RTOG进行的小组间合作等。MDACC SWOG计划的未来计划包括为初级教师扩展我们的SWOG辅导计划。MDACC将继续发挥其优势,在SWOG环境中开发多学科,创新的II期和III期研究。我们期待着领导SWOG在癌症研究,治疗和预防方面的努力,从而实现我们在德克萨斯州,国家和世界消除癌症的使命。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Cathy Eng其他文献

Cathy Eng的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Cathy Eng', 18)}}的其他基金

UT MD Anderson Cancer Center Network Lead Academic Participating Site (LAP)
UT MD 安德森癌症中心网络领导学术参与网站 (LAP)
  • 批准号:
    9024475
  • 财政年份:
    2014
  • 资助金额:
    $ 34.12万
  • 项目类别:
UT MD Anderson Cancer Center Network Lead Academic Participating Site (LAP)
UT MD 安德森癌症中心网络领导学术参与网站 (LAP)
  • 批准号:
    8838749
  • 财政年份:
    2014
  • 资助金额:
    $ 34.12万
  • 项目类别:
UT MD Anderson Cancer Center Network Lead Academic Participating Site (LAP)
UT MD 安德森癌症中心网络领导学术参与网站 (LAP)
  • 批准号:
    8605951
  • 财政年份:
    2014
  • 资助金额:
    $ 34.12万
  • 项目类别:
Determinants of Efficacy to the Akt Inhibitor Perifosine in Colorectal Cancer
Akt 抑制剂哌立福辛治疗结直肠癌疗效的决定因素
  • 批准号:
    8294604
  • 财政年份:
    2011
  • 资助金额:
    $ 34.12万
  • 项目类别:
Determinants of Efficacy to the Akt Inhibitor Perifosine in Colorectal Cancer
Akt 抑制剂哌立福辛治疗结直肠癌疗效的决定因素
  • 批准号:
    8192035
  • 财政年份:
    2011
  • 资助金额:
    $ 34.12万
  • 项目类别:
U10 Full Member Application Affiliated with SWOG
SWOG 附属 U10 正式会员申请
  • 批准号:
    8408827
  • 财政年份:
    2004
  • 资助金额:
    $ 34.12万
  • 项目类别:

相似海外基金

Cancer Center Administration
癌症中心管理
  • 批准号:
    10842468
  • 财政年份:
    2023
  • 资助金额:
    $ 34.12万
  • 项目类别:
SPORE University of Texas M. D. Anderson Cancer Center-Leukemia
SPORE 德克萨斯大学 MD 安德森癌症中心 - 白血病
  • 批准号:
    10911713
  • 财政年份:
    2023
  • 资助金额:
    $ 34.12万
  • 项目类别:
University of Kansas Cancer Center Midwest Pre-Clinical Imaging Center
堪萨斯大学癌症中心中西部临床前影像中心
  • 批准号:
    10795272
  • 财政年份:
    2023
  • 资助金额:
    $ 34.12万
  • 项目类别:
University of Hawaii Cancer Center CCSG
夏威夷大学癌症中心 CCSG
  • 批准号:
    10837568
  • 财政年份:
    2023
  • 资助金额:
    $ 34.12万
  • 项目类别:
UF Health Cancer Center Support Grant - Training Navigator Supplement
佛罗里达大学健康癌症中心支持补助金 - 培训导航补充
  • 批准号:
    10892335
  • 财政年份:
    2023
  • 资助金额:
    $ 34.12万
  • 项目类别:
Georgetown University Lombardi Comprehensive Cancer Center Support Grant
乔治城大学隆巴迪综合癌症中心支持补助金
  • 批准号:
    10771760
  • 财政年份:
    2023
  • 资助金额:
    $ 34.12万
  • 项目类别:
The University of Texas MD Anderson Cancer Center SPORE in Ovarian Cancer
德克萨斯大学 MD 安德森癌症中心 SPORE 在卵巢癌中的应用
  • 批准号:
    10709227
  • 财政年份:
    2023
  • 资助金额:
    $ 34.12万
  • 项目类别:
University of Kansas Cancer Center Paul Calabresi K12 Career Development Award for Clinical Oncology
堪萨斯大学癌症中心 Paul Calabresi K12 临床肿瘤学职业发展奖
  • 批准号:
    10647369
  • 财政年份:
    2023
  • 资助金额:
    $ 34.12万
  • 项目类别:
Mayo Comprehensive Cancer Center Grant (MICEO Supp) - Impact of Multi-Channel Communication Campaigns on Cancer Prevention, Control and Survivorship (CaPCaS) in Black, Hispanic, and Rural Populations
梅奥综合癌症中心拨款 (MICEO Supp) - 多渠道沟通活动对黑人、西班牙裔和农村人口癌症预防、控制和生存 (CaPCaS) 的影响
  • 批准号:
    10889628
  • 财政年份:
    2023
  • 资助金额:
    $ 34.12万
  • 项目类别:
Cancer Center Survivorship Research Forum
癌症中心生存研究论坛
  • 批准号:
    10608850
  • 财政年份:
    2023
  • 资助金额:
    $ 34.12万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了